Kevin ODare - Xtant Medical VP US
| XTNT Stock | USD 0.37 0.01 1.79% |
Insider
Kevin ODare is VP US of Xtant Medical Holdings
| Address | 664 Cruiser Lane, Belgrade, MT, United States, 59714 |
| Phone | 406 388 0480 |
| Web | https://www.xtantmedical.com |
Xtant Medical Management Efficiency
The company has return on total asset (ROA) of (0.1058) % which means that it has lost $0.1058 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0877) %, meaning that it created substantial loss on money invested by shareholders. Xtant Medical's management efficiency ratios could be used to measure how well Xtant Medical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Xtant Medical's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.01 in 2024, whereas Return On Capital Employed is likely to drop (0.15) in 2024. Change To Liabilities is likely to gain to about 1.9 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 16 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jaime Frias | Treace Medical Concepts | 62 | |
| John Ordway | Sight Sciences | N/A | |
| John Liu | Sight Sciences | N/A | |
| Thomas Timbie | Treace Medical Concepts | 66 | |
| Erin Liberto | Avita Medical | 49 | |
| Andre Marquette | Neuropace | N/A | |
| Marco Dolci | LivaNova PLC | 62 | |
| Alex Shvartsburg | LivaNova PLC | 54 | |
| Michael Hutchinson | LivaNova PLC | 53 | |
| Mark Saxton | Neuropace | 59 | |
| Derrick Sung | Pulmonx Corp | 51 | |
| Nabil Shabshab | Inogen Inc | 59 | |
| Geoffrey Rose | Pulmonx Corp | 50 | |
| Lisa Paul | Pulmonx Corp | 60 | |
| Daniel Owens | Treace Medical Concepts | 52 | |
| Martha Morrell | Neuropace | 67 | |
| Michael Favet | Neuropace | 54 | |
| Andrew Quick | Avita Medical | 53 | |
| Sam Park | Sight Sciences | 63 | |
| David MD | Sight Sciences | 54 | |
| Reay Brown | Sight Sciences | N/A | |
Management Performance
| Return On Equity | -0.0877 | ||||
| Return On Asset | -0.11 |
Xtant Medical Holdings Leadership Team
Elected by the shareholders, the Xtant Medical's board of directors comprises two types of representatives: Xtant Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xtant. The board's role is to monitor Xtant Medical's management team and ensure that shareholders' interests are well served. Xtant Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xtant Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sean Browne, CEO President | ||
| Scott Neils, Chief Officer | ||
| Kevin Brandt, Senior Vice President Chief Commercial Officer | ||
| Kevin ODare, VP US | ||
| Catherine Lundy, Vice Resources | ||
| Mark Schallenberger, Chief Officer |
Xtant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xtant Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0877 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | (0.1) % | ||||
| Current Valuation | 83.82 M | ||||
| Shares Outstanding | 139.01 M | ||||
| Shares Owned By Insiders | 7.83 % | ||||
| Shares Owned By Institutions | 65.12 % | ||||
| Number Of Shares Shorted | 197.47 K | ||||
| Price To Earning | (0.41) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xtant Stock Analysis
When running Xtant Medical's price analysis, check to measure Xtant Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xtant Medical is operating at the current time. Most of Xtant Medical's value examination focuses on studying past and present price action to predict the probability of Xtant Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xtant Medical's price. Additionally, you may evaluate how the addition of Xtant Medical to your portfolios can decrease your overall portfolio volatility.